Impact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective Study

Ibrahim Halil Acar¹, Sebnem Izmir Guner²*, Muzeyyen Aslaner Ak³, Mesut Gocer⁴, Erman Ozturk⁵, Figen Atalay⁶, Gulden Sincan⁷, Aysun Sentürk Yikilmaz⁸, Omer Ekinci⁹, Idris Ince¹⁰, Emine Gulturk¹¹, Nazli Demir¹², Ali Dogan¹³, Yildiz Ipek¹⁴ and Birol Guvenc¹.

¹ Adana Cukurova University, Faculty of Medicine, Hematology Department, Adana, Turkey
² Istanbul Gelisim University, Memorial Sisli Hospital Hematology&Bone Marrow Transplantation Unite, Istanbul, Turkey
³ Zonguldak Bulent Ecevit University, Faculty of Medicine, Hematology Department, Zonguldak, Turkey
⁴ Health Sciences University, Antalya Training and Research Hospital, Hematology Clinic, Antalya, Turkey
⁵ Istanbul Medeniyet University, Faculty of Medicine, Hematology Department, Istanbul, Turkey
⁶ Baskent University, School of Medicine, Department of Hematology, Ankara, Turkey
⁷ Atatürk University, Faculty of Medicine, Department of Hematology, Erzurum, Turkey
⁸ Denizli Governement Hospital, Hematology Clinic, Denizli, Turkey
⁹ Medicana International Istanbul, Adult Hematology and Bone Marrow Transplantation Center, Istanbul, Turkey.
¹⁰ Dr. Ersin Arslan Training and Research Hospital, Department of Hematology, Gaziantep, Turkey.
¹¹ Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Hematology Clinic, Istanbul, Turkey.
¹² Sisli Hamidiye Etfal Training and Research Hospital, Hematology Clinic, Istanbul, Turkey.
¹³ Van Yuzuncu Yil University, Faculty of Medicine, Department of Hematology, Van, Turkey.
¹⁴ Istanbul Kartal Dr. Lutfi Kirdar City Hospital, Hematology Clinic, Istanbul, Turkey.

Competing interests: The authors declare no conflict of Interest.

Abstract. Objectives: Patients with hematological malignancies have a high risk of mortality from coronavirus disease 2019 (COVID-19). This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematological malignancies and to determine risk factors associated with all-cause mortality.

Methods: A multicenter, observational retrospective analysis of patients with hematological malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study.

Results: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematological malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p<0.001) and had more comorbidities (p<0.05). In addition, there were significantly more patients with low lymphocyte percentage (p<0.001), thrombocytopenia (p<0.001), and high CRP (p<0.001) in the non-survived patients. Age ≥ 65years (p=0.017), cardiac comorbidities (p=0.041), and continuation of ongoing active therapy for hematological cancer (p<0.001) were the independent risk factors for the prediction of mortality.

Conclusions: In patients with hematological malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia
and non-Hodgkin lymphoma have the highest mortality rates. Older age, cardiac diseases, and continuation of ongoing active therapy for hematological cancer are the independent risk factors for mortality in hematological malignancy patients with COVID-19.

Keywords: Hematologic malignancies, COVID-19 virus disease, Mortality.

Citation: Acar I.H., Guner S.I., Ak M.A., Gocer M., Ozurt E., Atalay F., Sinanc G., Yukilmaz A.S., Ekinci O., Ince I., Gulturk E., Demir N., Dogan A., Ipek Y., Guvenc B. Impact of COVID-19 on outcomes of patients with hematologic malignancies: A multicenter, retrospective study. Mediterr J Hematol Infect Dis 2022,14(1): c2022074, DOI: http://dx.doi.org/10.4084/MJHID.2022.074

Published: November 1, 2022 Received: May 23, 2022 Accepted: October 11, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Following the declaration of COVID-19 as a global pandemic in March 2020 by the World Health Organization, several studies reported that the corrupted immunity seen in patients with COVID-19 infection causes poor outcomes in patients using chemotherapy, radiotherapy, and systemic immunosuppressive treatment. It has been reported that the overall mortality rate of cancer patients with COVID-19 infection could be as much as 40%. Hematological disorders such as myeloproliferative disorders, leukemia, lymphomas, and myelodysplastic syndromes are among the most vulnerable cohorts for COVID-19, considering the worse outcomes. The development of severe infections leads to worsening clinical outcomes in these patients. Hematological malignancies have been responsible for more severe clinical conditions due to COVID-19 infection than solid organ tumors.

In patients with hematological malignancies, such as leukemia, lymphoma, and myeloma, humoral and cellular immunosuppression can be a leading factor for the significantly increased mortality rates following COVID-19 infection. The immunosuppressive treatment modalities like chemotherapeutic agents or autologous or allogeneic hematopoietic stem cell transplantation may aggravate this situation. Although there is a significant concern about the increased morbidity and mortality risk due to COVID-19 infection, each hematological malignancy does not pose the same risk.

Previous studies have documented various high-risk factors for mortality, including the type of malignancy, advanced disease, comorbidity, age ≥ 60 years, need for intensive care unit admission, and recent systemic chemotherapy in hematological cancer patients infected with COVID-19. Because of the methodological heterogeneity, the reported outcomes show remarkable variations. However, determination of the prognostic factors for mortality of COVID-19 in hematological malignancy patients based on real-time data may be used to perform impactful decisions. That way, risk assessment and decision-making for effective supportive care would be possible.

This study aimed to evaluate the impact of COVID-19 on the mortality rates in patients with various hematological malignancies and determine the risk factors associated with all-cause mortality.

Materials and Methods. Study. This study was a multicenter, observational retrospective analysis of patients with hematological malignancies who had been diagnosed with COVID-19 between July 2020 and December 2021. Fourteen tertiary centers specialized in hematological diseases throughout Turkey participated in the study. The local ethical committee approved the study (Institutional Review Board of Memorial Sisli Hospital, Istanbul, Turkey, Jul 28, 2020, Number: 003). The researchers agreed to apply the principles of the Helsinki Declaration. However, written consent could not be taken due to the study’s retrospective design and the unamity of data.

Patients. The patients with newly diagnosed hematological malignancies or ongoing treatment/follow-up were evaluated. The specific hematological malignancies were Hodgkin and non-Hodgkin lymphoma, multiple myeloma, leukemia (acute myeloid, acute and chronic lymphoid, chronic myeloid, chronic myelomonocytic, hairy cell), myelodysplastic syndromes, polycythemia vera, essential thrombocytopenia, myelofibrosis, histiocytosis, and mastocytosis. The severity and the treatment modality (home isolation, outpatient, and inpatient treatment) of COVID-19 and the remission status of the hematological malignancies were not considered for the inclusion of the cases. The diagnosis of COVID-19 was performed and proved via a positive qualitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) on the nasal and oropharyngeal swab samples. The inclusion criteria were as follows: age over 18 years, diagnosis of hematological malignancy before COVID-19, and RT-PCR proved diagnosis of COVID-19. The patients with clinical findings suspicious of COVID-19...
but without positive RT-PCR (clinical diagnosis) and presumed second primary cancers were excluded. A standardized protocol for diagnosing and treating COVID-19 based on the Turkish Ministry of Health Guidelines was used for all patients.¹⁵

Variables. A Microsoft Excel spreadsheet format was used in collecting and recording the related data. All centers entered their data into this predetermined sheet and electronically submitted it in an anonymized form to the study's principal investigator/data processor. The entries were checked for duplicated data.

Demographic data (age, sex) and clinical characteristics (admission symptoms, severe obesity, comorbidities) were recorded. The body mass index value equal to or higher than 40 kg/m² was defined as class III obesity.¹⁶ The patients' presenting symptoms at the time of admission for COVID-19 were also searched and recorded. The type of baseline hematological cancer and past and ongoing treatment details were collected using the hospital information system of each center and the patient's medical files. The ongoing treatment was defined as having the treatment within 30 days before COVID-19 diagnosis.⁵,¹⁷

The laboratory parameters at the diagnosis of COVID-19 [leukocyte and platelet counts, lymphocyte percentage, C-reactive protein (CRP), and D-dimer] were investigated and categorized as low, normal, or high using each laboratory's lower and upper limits. In addition, we categorized the treatment modalities for hematological malignancies as conventional chemotherapy, targeted therapies (small-molecule inhibitors and monoclonal antibodies), immunotherapy (checkpoint inhibitors), and immunomodulatory.¹⁴ Any change in the chemotherapy protocols associated with COVID-19 was noted.

The antiviral drugs, broad-spectrum antibiotics, antifungal and antimarial medications, glucocorticoids, immune-modulating agents (Interleukin-6 and Janus kinase inhibitors), immune plasma therapy, and other medical modalities for COVID-19 were recorded. In addition, the adverse effects due to COVID-19 treatment were noted.

Statistical analysis. All-cause mortality was the primary outcome of this study; therefore, the patients were grouped as the non-survivors and survivors. We compared the groups regarding demographic and clinical characteristics; however, the factors impacting the development of all-cause mortality were also analyzed.

For descriptive statistics, mean ± standard deviation was used to present continuous data with normal distribution. A Median with minimum-maximum values was applied for continuous variables without normal distribution. Numbers and percentages were used for categorical variables. The Shapiro-Wilk and Kolmogorov-Smirnov tests analyzed the normal distribution of the numerical variables. Q-Q plots and histograms also checked the normal distribution pattern.

The Mann-Whitney U test compared two independent groups for the variables without normal distribution. The Pearson Chi-Square, Fisher's Exact, and Fisher Freeman Halton tests were used to compare the differences between categorical variables in ²×² and RxC tables.

Binary logistic regression was performed to analyze the factors that impact the development of mortality. In addition, statistically or clinically significant factors regarding hematological malignancies in the univariate analysis were included in the multivariate analysis.

For statistical analysis, IBM SPSS Statistics V.21 was used. All statistical analyses determined the significance level (p-value) at 0.05.

Results. There were 569 patients in the study group with a median age of 59 years (18-91 years). There was a higher prevalence of elderly (≥65 years) (61.3%) and male patients (57.6%). Non-Hodgkin lymphoma and multiple myelomas were the two most common hematological malignancies in 125 (22.0%) and 103 patients (18.1%). Hypertension was the most frequent comorbidity (28.3%), followed by respiratory diseases (16.5%) and diabetes mellitus (16.0%) in the study group. The study cohort's baseline demographic and clinical characteristics are given in Table 1.

One hundred and sixty-seven patients did not survive, with an all-cause mortality rate of 29.3%. Considering all cases, 154 cases (92.2%) were COVID-related mortality. We hospitalized 410 patients (72.1%) for COVID-19 treatment. The hospitalization rate was significantly higher in the non-survived group (99.4% vs.60.7%, p<0.001). The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), non-Hodgkin lymphoma (36.8%), and multiple myeloma (31.1%), and myelodysplastic syndromes (29.5%).

The comparison of the demographic and clinical characteristics of the patients revealed that the non-survivors were significantly older (median age 64 vs. 57 years, p<0.001) than the survivors. The proportion of patients aged 65 years or more was significantly higher in the non-survived group (p=0.001). Sex distribution was similar in the groups (p=0.780). Comparing the frequencies of the hematological malignancies revealed no significant difference in the survived and non-survived patients (p=0.781). The incidences of hypertension (p=0.019), respiratory diseases (p=0.047), cardiac diseases (p=0.003), and chronic renal failure (p=0.026) were significantly higher in patients who were non-survived. The survival and non-survived patients' clinical characteristics were similar (Table 1).

The distribution of the presenting symptoms is detailed in Table 2. Fever (76.3%), fatigue (58.3%),...
Table 1. Demographic and clinical characteristics of the study group.

| Demographic and clinical characteristics | Overall (n=569) | Survivors (n=402) | Non-survivors (n=167) | P |
|-----------------------------------------|----------------|-------------------|-----------------------|---|
| Age †‡ | 57.2 ±17.6 (59, 18-91) | 55±18 (57, 18-91) | 62±16 (64, 20-89) | <0.001 |
| Age group § | <65 years | 349 (61.3) | 264 (65.7) | 85 (50.9) | 0.001 |
| | ≥65 years | 220 (38.7) | 138 (34.3) | 82 (49.1) | 0.780 |
| Sex § | Female | 241 (42.4) | 172 (42.8) | 69 (41.3) | 0.780 |
| | Male | 328 (57.6) | 230 (57.2) | 98 (58.7) | 0.780 |
| Type of hematological cancer § | Non-Hodgkin lymphoma | 125 (22) | 79 (19.7) | 46 (27.5) | 0.781 |
| | Multiple myeloma | 103 (18.1) | 71 (17.7) | 32 (19.2) | 0.001 |
| | AML | 79 (13.9) | 44 (10.9) | 35 (21.0) | 0.001 |
| | CLL | 66 (11.6) | 57 (14.2) | 9 (5.4) | 0.001 |
| | MDS | 44 (7.7) | 31 (7.7) | 13 (7.8) | 0.001 |
| | ALL | 42 (7.4) | 28 (7.0) | 14 (8.4) | 0.001 |
| | CML | 27 (4.7) | 23 (5.7) | 4 (2.4) | 0.001 |
| | Hodgkin lymphoma | 25 (4.4) | 21 (5.2) | 4 (2.4) | 0.001 |
| | Polycythemia vera | 15 (2.6) | 13 (3.2) | 2 (1.2) | 0.001 |
| | Essential thrombocythemia | 14 (2.5) | 10 (2.5) | 4 (2.4) | 0.001 |
| | Myelofibrosis | 13 (2.3) | 11 (2.7) | 2 (1.2) | 0.001 |
| | Others | 16 (2.9) | 14 (3.5) | 2 (1.2) | 0.001 |
| Obesity Class III § | 8 (1.4) | 6 (1.5) | 2 (1.2) | 0.001 |
| Cancer § | 7 (1.2) | 3 (0.7) | 4 (2.4) | 0.001 |
| Previous hematopoietic stem cell transplant § | 4 (0.7) | 3 (0.7) | 1 (0.6) | 0.001 |
| Immune deficiency § | Hypertension | 15 (2.6) | 12 (3.0) | 3 (1.8) | 0.001 |
| | Respiratory diseases | 161 (28.3) | 102 (25.4) | 59 (35.3) | 0.001 |
| | Diabetes mellitus | 94 (16.5) | 58 (14.4) | 36 (21.6) | 0.001 |
| | Cardiac diseases | 91 (16.0) | 59 (14.7) | 32 (19.2) | 0.001 |
| | Chronic renal failure | 79 (13.9) | 44 (10.9) | 35 (21.0) | 0.001 |
| | Cerebrovascular diseases | 26 (4.6) | 13 (3.2) | 13 (7.8) | 0.001 |
| | Psychiatric disorders | 7 (1.2) | 4 (1.0) | 3 (1.8) | 0.001 |
| | Others | 13 (2.3) | 7 (1.7) | 6 (3.6) | 0.001 |

†: mean ± standard deviation, ‡: median [min-max], §: n (%). Others: Hairy cell leukemia (n=6), histiocytosis (n=5), CMML (n=4), mastocytosis (n=1). AML: acute myeloid leukemia, CLL: chronic lymphoid leukemia, MDS: myelodysplastic syndromes, ALL: acute lymphoid leukemia, CML: chronic myeloid leukemia.

Table 2. COVID-19 symptoms and signs at diagnosis.

| Admission symptoms § | Overall (n=569) | Survivors (n=402) | Non-survivors (n=167) | P |
|----------------------|----------------|-------------------|-----------------------|---|
| Fever | 434 (76.3) | 290 (72.1) | 144 (86.2) | <0.001 |
| Fatigue | 332 (58.3) | 223 (55.5) | 109 (65.3) | 0.032 |
| Coughing | 297 (52.3) | 202 (50.2) | 95 (56.9) | 0.167 |
| Myalgia | 273 (48.0) | 197 (49.0) | 76 (45.5) | 0.462 |
| Dyspnea | 269 (47.3) | 155 (38.6) | 114 (68.3) | <0.001 |
| Arthralgia | 186 (32.7) | 135 (33.6) | 51 (30.5) | 0.494 |
| Headache | 144 (25.3) | 108 (26.9) | 36 (21.6) | 0.205 |
| Sore throat | 137 (24.1) | 100 (24.9) | 37 (22.2) | 0.520 |
| Irritability/confusion | 105 (18.5) | 62 (15.4) | 43 (25.7) | 0.006 |
| Anosmia | 69 (12.1) | 46 (11.4) | 23 (13.8) | 0.481 |
| Diarrhea-nausea/vomiting | 47 (8.3) | 27 (6.7) | 20 (12.0) | 0.045 |
| Chest pain | 45 (7.9) | 21 (5.2) | 24 (14.4) | 0.001 |
| Abdominal pain | 19 (3.3) | 11 (27.0) | 8 (4.8) | 0.211 |
| Disgusia | 14 (2.5) | 10 (2.5) | 4 (2.4) | 1.0 |
| Rinorrhea | 2 (0.4) | 2 (0.5) | 0 (0) | 1.0 |

§: n (%).
coughing (52.3%), myalgia (48.0%), and dyspnea (47.3%) were the most common symptoms at the admission of the patients. There were significant differences in the frequencies of the admission symptoms between the survivors and non-survivors. The non-survived patients more frequently have had fever (p<0.001), fatigue (p=0.032), dyspnea (p<0.001), irritability/confusion (p=0.006), gastrointestinal symptoms (p=0.045), and chest pain (p=0.001).

There were 329 patients (57.8%) in the study group with ongoing active oncological treatment. We found a significant difference considering the use of any treatment. The proportion of non-survived patients with on-therapy was significantly higher than those of the survived patients (58.9% vs. 46.8%, p=0.001). The distribution of the oncological treatment modalities revealed no significant difference (Table 3). The oncological treatment was stopped in 299 patients (90.6%) due to COVID-19. The proportion of patients with ongoing therapy after COVID-19 was significantly lower in the non-survived patients (p=0.028).

The results of the laboratory investigations at the admission are given in Table 4. There were significant differences in leukocyte count, lymphocyte percentage, platelet count, CRP, and D-Dimer between the survived and non-survived patients. The median values of platelet counts and the percentage of lymphocytes were significantly lower in the non-survived patients (p<0.001 and p<0.001, respectively). In addition, we found significantly higher CRP and D-dimer values in the non-survived group (p<0.001 and p<0.001).

Table 5 presents the details of the treatment used for COVID-19. 77.9% of the patients received antiviral medications, and glucocorticoids were used in 299 patients (52.5%). Other details are summarized in Table 5.

We detected a total of 84 side effects in the study group. Nausea/vomiting, elevated liver enzymes, and neutropenia were the most frequent complications in 23, 18, and 11 patients. The development of side effects

---

**Table 3. Details of ongoing active therapy for hematologic cancer (n=329).**

| Type of therapy  | Overall (n=329) | Survivors (n=214) | Non-survivors (n=115) | p  |
|------------------|-----------------|-------------------|-----------------------|----|
| Conventional chemotherapy | 225 (68.4) | 139 (65.0) | 86 (54.8) | 0.082 |
| Targeted therapy | 71 (21.6) | 49 (22.9) | 22 (19.1) | 0.483 |
| Immunotherapy | 93 (28.3) | 57 (26.6) | 36 (31.3) | 0.372 |
| Monoclonal antibody | 49 (14.9) | 32 (15.0) | 17 (14.8) | 1.0 |

**Table 4. Laboratory investigations of the survived and non-survived patients.**

| Laboratory investigation  | Survivors (n=402) | Non-survivors (n=167) | p  |
|---------------------------|-------------------|-----------------------|----|
| Leukocyte count (x10^3/L) | 5120 (0.05-198200) | 3800 (0-188000) | 0.053 |
| Leukocyte groups | Low | 122 (30.3) | 73 (43.7) | 0.461 |
| Normal | 200 (49.8) | 53 (31.7) |
| High | 80 (19.9) | 41 (24.6) |
| Lymphocyte (%) | Low | 15 (0-100) | 10 (0-95) | <0.001 |
| Normal | 212 (52.7) | 113 (67.7) |
| High | 190 (48.3) | 54 (32.3) |
| Platelet count (x10^3/L) | 146000 (2-2760000) | 40000 (23-993000) | <0.001 |
| Platelet groups | Low | 196 (48.8) | 141 (84.4) | <0.001 |
| Normal | 206 (51.2) | 26 (15.6) |
| C-reactive protein (mg/dL) | Low | 30 (1-257) | 130 (2-560) | <0.001 |
| Normal | 53 (13.1) | 3 (1.8) | <0.001 |
| C-reactive protein groups | High | 349 (86.9) | 164 (98.2) |
| D-dimer (ng/mL) | Low | 939 (0-19000) | 4200 (9-85000) | <0.001 |
| High | 91 (22.6) | 20 (12.0) | 0.166 |

---

1: median [min-max]. 2: n (%).
associated with COVID-19 treatment was more frequently seen in non-survived patients (p<0.001).

Binary logistic regression analysis revealed that age ≥ 65 years (OR=1.669, CI 95%:1.096-2.542, p=0.017), cardiac diseases (OR=1.748, CI 95%:1.024-2.984, p=0.041), and the continuation of ongoing active therapy for hematological cancer (OR=2.510, CI 95%:1.707-3.691, p<0.001) were the independent risk factors for the prediction of mortality in hematological cancer patients with COVID-19 infection (Table 6).

Discussion. This study presented the outcomes of 569 COVID-19 patients treated due to hematological malignancies in 14 tertiary centers in Turkey. The all-cause mortality rate was 29.3% in the study group. The older patients with comorbidities were the most susceptible group to mortality. Older age, cardiac comorbidities, and continuation of ongoing active therapy for hematological cancer during the COVID-19 pandemic were the independent risk factors for mortality in the binary logistic regression model.

Several studies have focused on the outcomes of COVID-19 in hematological malignancy patients. The European Hematology Association Survey (EPICOVIDEHA) published the outcomes of 3801 patients with hematological malignancy. Non-Hodgkin lymphoma, multiple myeloma, chronic lymphoid leukemia, acute myeloid leukemia, and myelodysplastic syndromes were more frequent than other diseases. The frequency rank of the diseases in our study was almost similar to the findings of this cohort. In population-based data from the Turkey Ministry of Health, non-Hodgkin lymphoma was the most frequent malignancy seen in almost one-third of 1480 laboratory-confirmed COVID-19 patients. Other studies documented many COVID-19 cases with non-Hodgkin lymphoma and multiple myeloma. In the EPICOVIDEHA study, the incidence of acute myeloid leukemia was 12.5%, like 13.9% in our study. Although the authors thought this disease was a rare malignancy compared to the other types, Wood et al. reported that acute leukemia was the most common type of cancer, followed by non-Hodgkin lymphoma in the ASH Research Collaborative COVID-19 Registry for Hematology. So, it should be kept in mind that the heterogeneity of the hematological diagnoses and their treatment modalities leads to difficulty in evaluating the outcomes.

In the studies investigating the mortality rate of COVID-19 patients with hematological malignancy...
hematological malignancy patients after they were infected with COVID-19, the overall mortality rates were reported to be up to 40%.\textsuperscript{2,5,7,9,17,21,22} Vijenthira et al.\textsuperscript{4} reviewed the outcomes of 3377 patients with hematological malignancies and COVID-19 in a systematic review and meta-analysis. They found a higher mortality risk in older and hospitalized patients. Recent cancer treatment was not associated with mortality. Several authors used different time points to determine mortality rates ranging from 14 to 45 days leading to conflicting evaluations.\textsuperscript{9,13,22} The overall mortality rate in the European Hematology Association Survey was 31.2%.\textsuperscript{2} The current study's all-cause mortality rate was 29.3% during the in-hospital follow-up period. We think our mortality rate was similar to the previously published studies. Higher mortality rates have been explicitly detected in patients with severe COVID-19.\textsuperscript{9} It has also been mentioned that COVID-19 caused higher mortality rates in patients with hematological cancer than those with solid tumors.\textsuperscript{18} So, the methodological differences, different study date intervals regarding the various waves of the COVID-19 pandemic, and the evaluation periods for mortality should be considered when comparing the outcomes.\textsuperscript{19} In light of these data, we may think that COVID-19 leads to higher mortality rates in patients with hematological malignancies.\textsuperscript{2,5,7,14}

The possible association between the type of hematological cancer and mortality is another speculated issue. According to the European Survey, the highest mortality rates were detected in patients with acute myeloid leukemia and myelodysplastic syndromes.\textsuperscript{5} In the UK Coronavirus Cancer Monitoring Project (UKCCMP), acute leukemia and myeloma had the highest mortality compared to the other hematological cancer types.\textsuperscript{14} A subgroup analysis of hematological malignancies was not performed in Vijenthira's review paper.\textsuperscript{4} However, the variances according to the type of malignancy have been studied by others.\textsuperscript{6} The relatively lower or higher mortality rates have been reported in patients with lymphoma or acute myeloid leukemia infected with COVID-19.\textsuperscript{2,6,14} In the current study, the five diseases with the highest mortality rates (acute myeloid leukemia, acute lymphoid leukemia, non-Hodgkin lymphoma, multiple myeloma, and MDS) were similar to the previous studies. There should be several explanations for the worst outcome and highest mortality rates in these specific hematological malignancies. Age, profound immunodeficiency status due to the underlying disease or its treatment, and any possible delay in the treatment have been speculated to explain the poor outcomes in these patients.\textsuperscript{2,22}

The impact of hematological cancer treatment and its type is another conflicting issue. The features of treatment modalities for hematological malignancies are thought to be associated with the outcomes of COVID-19.\textsuperscript{9} However, in the UKCCMP cohort, the authors found no association between cytotoxic chemotherapy, anti-CD 20 therapy, and mortality.\textsuperscript{14} Although there were no significant differences in the frequencies of the cancer types and the ongoing active treatment modalities for hematological cancer between the survivors and non-survivors, the continuation of the ongoing active therapy for hematological cancer was one of the independent risk factors for mortality in our study. It is not easy to show the exact cause-and-effect relationships in a retrospective study. Besides, comparing the mortality rates in the different studies may be problematic regarding the patients' different demographic and clinical characteristics. So, prospective studies are needed to overcome the controversies between the studies.

Previous studies reported various risk factors for mortality. Older patients were more susceptible to mortality.\textsuperscript{2,13,14,22} Although different cut-off values to define elderly people have been used, we may conclude that patients over 65 or 70 have higher mortality rates. In the present study, older age (≥65 years) was significantly associated with the development of mortality. We think that as the patient's age increases, comorbidities and other clinical situations might reflect the increased mortality risk more appropriately. Age, comorbidities, neutrophilia, lymphopenia, and high CRP were significant predictors of mortality in the UKCCMP cohort.\textsuperscript{14} Thrombocytopenia was another significant factor associated with higher mortality risk.\textsuperscript{24} However, others found no significant impact on mortality of age, sex, comorbidity, leukocyte, and lymphocyte counts.\textsuperscript{7} In the current study, older age, cardiac comorbidities, and continuation of ongoing active therapy for hematological cancer were the independent risk factors for mortality in the multivariate model. It is unsurprising to obtain controversial findings due to the different patient and tumor characteristics.\textsuperscript{22}

Different treatment modalities based on the severity and remission status of COVID-19 may impact the outcomes of patients with hematological malignancies. Although we did not use the severity grading of the infection, the inclusion criteria for COVID-19 infection were well-standardized based on the national treatment protocols. Besides, various factors, including the intensity of immunosuppressive treatment and the type of hematological cancer and its treatment modalities, might contribute to the differences in the outcomes of the patients infected with COVID-19.\textsuperscript{9} Several authors also proposed that in their treatment's pre-induction, induction, and refractory phases, hematological malignancy patients might have weaker immunity than those in the maintenance phase.\textsuperscript{23} Azhdari Tehrani et al. found that the pre-induction and induction phases of the treatment for hematological cancer were significantly associated with increased mortality for different hematological cancers.\textsuperscript{23} A systematic review and meta-
analysis by Naimi et al. analyzed that the weakening of the immune system is a common consequence of anti-tumor therapies. Previous studies showed that anti-tumor therapies during the first 14 days of COVID infection caused poor prognosis in cancer patients. Avoidance of the treatment modalities leading to an immunosuppressive status has been recommended. Although the types of ongoing active therapy for hematological cancer were not associated with the development of mortality in this patient group, the continuation of these therapies was the independent risk factor for mortality. We also could not discriminate between the different phases of the therapies. So, we think the treatment strategies for patients with hematological cancer should be tailored considering the current status of cancer and COVID infection simultaneously.

The patients' symptoms may show variations considering the underlying malignancy and COVID-19. The most frequent symptoms were fever, weakness, cough, and dyspnea. We detected significant differences in the incidences of the admitting symptoms between the survivors and non-survivors. Fever, fatigue, dyspnea, irritability/confusion, gastrointestinal complaints, and chest pain were more frequently seen in complaints, and chest pain were more frequently seen in dyspnea, irritability/confusion, gastrointestinal differences in the incidences of the admitting symptoms cough, and dyspnea.

We detected significant differences in the incidences of the admitting symptoms between the survivors and non-survivors. Fever, fatigue, dyspnea, irritability/confusion, gastrointestinal complaints, and chest pain were more frequently seen in the non-survivors. However, the triad of "malignancy, infection, and treatment" may lead to complexity in this patient group. So, we may not be sure of the exact role of these significant differences in the mortality rates. Besides, the side effects developed during the COVID-19 treatment would be due to the viral exposure that could not be differentiated using this retrospective data. Although a predetermined worksheet was used, incomplete data entry was considered possible.

In conclusion, coexistent COVID-19 was significantly associated with a higher mortality rate in elderly patients with more comorbidities in patients with hematological malignancies. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma had the highest mortality rates. Older age, cardiac diseases, and continuation of ongoing active therapy were the independent risk factors for mortality in hematological malignancies with COVID-19.

Acknowledgment. All authors would like to thank the colleagues who participated in this study.

References:

1. Papakonstantinou E, Dragoumi K, Efthimiadou A, Palaiogeorgou AM, Pierrou K, Mitsis T, Chrousos GP, Bacopoulou F, Vlachakis D. Haematological malignancies implications during the times of the COVID-19 pandemic. Oncol Lett. 2021;22(6):856. https://doi.org/10.3892/ol.2021.13117

PMID: 34777590

2. Pagano L, Salmantón-García J, Marchesi F, Busca A, Corradiini P, Hoeingl M, Klimko N, Koehler P, Pagliau A, Passamonti F, Verga L. Covid-19 in hematological cancer survivors. A retrospective study. J Hematol Oncol. 2022;15(1):168. https://doi.org/10.1186/s13045-021-01177-0

PMID: 34699563

3. Pinato DJ, Zambrini A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Messa R, Segui E, Biello F, Generali D, Grisanti S, Rizzo G, Liberti M, Maconi A, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Carrobo A, Bruna R, Benefis S, Marrari A, Wuerstlein R, Carmona-Garcia MC, Chopra N, Tondin C, Mirallas O, Tovazzi V, Betti M, Provenzano S, Fotia V, Cruz CA, Dalla Pria A, D’Avanzo F, Evans JS, Saoudi-González N, Felip E, Galazi M, García-Fructuoso I, Lee AJX, Newsom-Davis T, Patriarca A, García-Illésedes D, Reyes R, Dileo P, Sharry R, Wong YNS, Ferrante D, Marco-Hernández J, Sureda A, Malaquía R, Ruiz-Camps I, Gaidano G, Rimassa L, Chiudinelli L, Izuquiza M, Cabrita A, Franchi M, Santoro A, Prat A, Tabernero J, Gennari A. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov. 2020 Jul 31;10(1):1465–74. https://doi.org/10.1158/2159-8290.CD-20-0773

PMID: 32737082

4. Vijenthira A, Gong IV, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razzahanbey J, Riches JC, Zwicker J, Patell R, Vekemans MC, Scarló L, Chaitzkonstantinou T, Yildiz H, Lattenstein R, Mantzaris I, Wood WA, Hicks LK. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020 Dec 17;136(25):2881-2892. https://doi.org/10.1182/blood.2020088224

PMID: 33131551

5. García-Suárez J, de la Cruz J, Cédiño Á, Llamas P, Duarte R, Jiménez-Yuste V, Hernández-Rivas JÁ, Gil-Manso R, Kwon M, Sánchez-Godoy P, Martínez-Barranco P, Colás-Lahuerta B, Herrera P, Benito-Parra L, Alegre A, Velasco A, Matilla A, Alaez-Usón MC, Martos-Martínez R, Martínez-Chamorro C, Susana-Quiróz K, Del Campo JF, de la Fuente A, Herráez R, Pascual A, Gómez E, Pérez-Oteyza J, Ruiz E, Alonso A, González-Medina J, Martín-Buitrago LN, Canales M, González-Gascón I, Vicente-Ayuso MC, Valentino S, Roa MG, Montelú PE, López-Jiménez J, Escobar CE, Ortiz-Martín J, Diez-Martín JL, Martínez-Lopez J, Asociación Madrileña de Hematología y Hemoterapia (AMHH). Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):133. https://doi.org/10.1186/s13045-020-00970-7

PMID: 33032660

6. Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, Meers S, Rizzato C, Angelini D, Al-Khabori M, Garcia-Sanz R, Biernat MM, Tisc MM, Salat M, Rahimli M, Colović M, Schönlein M, Calbaccho M, Tascini C, Miranda-Castillo C, Khanna N, Méndez GA, Petzer S, Novák B, Jesson B, Delury R, Lamure S, Nucci M, Zambrotta G, Seval J; Asociación Madrileña de Hematología y Hemo... (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. https://doi.org/10.1186/s13045-021-01177-0

PMID: 34699563
M. Fracciolla N, Marchetti M, Scattolin A, Tisi MC, Cuneo A, Della Porta M, Trentin L, Turmini G, Gherlinzoni F, Tufari A, Galimberti S, Bocchia M, Cardinali V, Cilloni D, Corso A, Armiento D, Rigacci L, La Barbera EO, Gambacorti-Passerini C, Visani G, Vallisa D, Venditti A, Selleri C, Conconi A, Tosi P, Lanza F, Cardoni A, Krampera M, Corradi P, Passamonti F, Merli F; FITHEM investigators. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. 2022;6(11):3277-3288. https://doi.org/10.1182/bloodadvances.2021005691

PMID: 34644085

7. Tugluoglu P, Albayrak M, Tugluoglu M, Ozturk HBA, Aras MR, Saglam B, Maral S. The outcome of COVID-19 in patients with hematological malignancy. Memo. 2022;15(1):83-89. https://doi.org/10.12244/2021-00775-5

PMID: 34904893

8. Pagnano KB, Peralta EH, Navarro JR, David Salas LDR, Delgado N, Morraghi B, Torelli ACM, Perobelli LM, Fechino L, Quixada ATS, Funke V, Bendit I, Seguro FS, Pilleux L, Bortolin J, Lourenço AGL, Sapelli J, Nucci FM, Pavlovsky C, Oliveira LDC, Moura MS, Palma L, Gonçalves NN, Conchon M, Hakansson POM, Almeida LU, Zulli R, de Souza CA, Boqumpani CM. COVID-19 in chronic myeloid leukemia patients in Latin America. Leuk Lymphoma. 2022;63(12):3212-3218. https://doi.org/10.1080/10428194.2021.1950709

PMID: 34254886

9. Jain A, Nayak L, Kulkarni UP, Mehra N, Yanamandra U, Kayal S, Damodar S, John JKM, Mehta P, Singh S, Munot P, Selvarajan S, Rashadkhursheed V, Lad D, Kapoor R, Dubhashi B, Bharath RS, Jain H, Jayachandran PK, Lakshmanan J, Mani T, Thorat J, Das S, Karunamurthy O, George B, Sengar S, Malhotra P. Outcomes of patients with hematological malignancies and COVID-19 from the Hematologic Cancer Registry of India. Blood Cancer J. 2022;12(1):1. https://doi.org/10.1038/s41408-021-00599-w

PMID: 34987161

10. Scarío L, Chatzikonstantinou T, Rigolín GM, Quaresmini G, Motta M, Vitale C, García-Marco JA, Hernández-Rivas JA, Mirás F, Baille MA, Masqué J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Scuffo L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Ozturk HBA, Aras MR, Saglam B, Korkmaz S, Dal MS, Korkmaz S, Campton NA, Cheng VWT, Collins G, Curley HM, Earwaker P, Fittall Lee LYW, García C, Itchaki G, Špaček M, De Paoli MR, Del Poeta G, Farina L, Foglietta M, Vandenberghe E, Trentin L, Wasik MB, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth Brown AC, Palles C, Powles T, Protheroe EA, Purshouse K, Selleri C, Conconi A, Tosi P, Lanza F, Candoni A, Krampera M, Barbera EO, Gambacorti-Passerini C, Visani G, Vallisa D, Venditti A, Selleri C, Conconi A, Tosi P, Lanza F, Cardoni A, Krampera M, Corradi P, Passamonti F, Merli F; FITHEM investigators. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. 2022;6(11):3277-3288. https://doi.org/10.1182/bloodadvances.2021005691

PMID: 34644085

11. Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth S, Campton NA, Cheng VWT, Collins G, Curley HM, Earwaker P, Pittall MW, Genmaas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJX, Lee RJ, Lee SM, McKenzie H, Middleton CP, Muragauesu N, Newsom-Davis T, Olsson-Brown AC, Palles C, Powles T, Protheroe EA, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Topping O, Turnbull CD, White E, Wolk A, Zeleniuch-Jacquotte A, Hartge P. Association between class III obesity (BMI of 40-59 kg/m²) and mortality: a pooled analysis of 20 prospective studies. PLoS Med. 2014;11(7):e1001673. https://doi.org/10.1371/journal.pmed.1001673

PMID: 25083901

12. Romano A, Cerchione C, Conticello C, Filetti S, Bulla A, Chiarenza A, Del Faro V, Leotta S, Markovic U, Motta G, Parisi M, Stagno F, Palumbo GA, Di Raimondo F. Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV-2 Infection. Cancers (Basel). 2022;14(5):1173. https://doi.org/10.3390/cancers14051173

PMID: 35267478

13. Yegonoglu TN, Ata N, Altuntas F, Basci S, Dal MS, Korkmaz N, Namdaroglu S, Basturk H, Facbekiroglu T, Dogu MH, Berber I, Dal K, Erkurt MA, Turgut B, Ulgu MM, Celik O, Imrat E, Birinci S. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93(12):1099-1104. https://doi.org/10.1002/jmv.26404

PMID: 32776581

14. Regalado-Artamendi I, Jiménez-ubieto A, Hernández-Rivas JA, Navarro B, Núñez L, Aizoa C, Córdoba R, Pérez Salazar M, Estival P, Chozas C, Cebrián-Sanz E, López-Jiménez I, Matilla A, Herrera MR, Penalva MJ, García-Suárez J, Díez-Martín JL, Bastos-Oreiro M. Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study. Hemasphere. 2021;5(3):ea538. https://doi.org/10.1111/1756-4669.14035

PMID: 33604516

15. Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, Anderson KC, Goldberg AD, Pennell NA, Niemeyer CM, Tucker E, Hewitt K, Plovnick RM, Hicks LK. Outcomes of patients with hematological malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4(23):5966-5975. https://doi.org/10.1182/bloodadvances.2020001370

PMID: 33278301

16. Modemann F, Niederwieser C, Weisell K, Bobekemeyer C, Fiedler W, Ghandili S. COVID-19 in patients with hematological malignancies. Leuk Lymphoma. 2022;63(3):664-671. https://doi.org/10.1080/10428194.2021.1997262

PMID: 34668809.

17. Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, Gómez-Catalán I, Coll R, De La Fuente J, Luna A, Merchán G, Donchea A, De Miguel D, Serrano A, Pérez C, Díaz C, López JL, Saiz AJ, García C, Zudaire T, Martínez D, Jurado M, Calbayo M, Vázquez L, García-Cadenas I, Cox L, Pimentel AI, Bustos G, Nieto A, Fernández-Palillo J, Galdeano C, Solano C, Valero M, Espigado I, Saldívar R, Sisinni L, Ribera JM, Buey J, Gómez S, Ortega MC, Tajes M, Gómez-Vicent M, Fernández N, Talarca J, Montoya MC, Cedillo A, Sureda A; Infections Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21.
23. Azhdari Tehrani H, Ramezaninejad S, Mardani M, Shokouhi S, Darnahal M, Hakamifard A. Hematologic malignancies and COVID-19 infection: A monocenter retrospective study. Health Sci Rep. 2022;5(3):e638. https://doi.org/10.1186/s41375-020-0025-7
PMID: 32561842

24. Naimi A, Yashmi I, Jebeleh R, Imani Mofrad M, Azimian Abhar S, Jannesar Y, Mohsen Heidary M, Pakzad R Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis. J Clin Lab Anal. 2022;36(5):e24387. https://doi.org/10.1002/jcla.24387
PMID: 35385130

25. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M. Affiliations expand Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894-901. https://doi.org/10.1016/j.annonc.2020.03.296
PMID: 32224151

26. Ferrara F, Zappasodi P, Roncoroni E, Borlenghi E, Rossi G. Impact of Covid-19 on the treatment of acute myeloid leukemia. Leukemia. 2020;34(8):2254-2256. https://doi.org/10.1038/s41375-020-0025-7
PMID: 32561842